双歧杆菌三联活菌胶囊/散治疗新生儿黄疸临床疗效的Meta分析

Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules/Powder for the treatment of neonatal jaundice:A Meta-analysis

目的采用Meta分析方法评价双歧杆菌三联活菌胶囊/散治疗新生儿黄疸的临床疗效。方法计算机检索中国知网、万方、维普、PubMed、Embase、Web of Science数据库,检索时限均从建库至2015年12月,收集国内外应用双歧杆菌三联活菌胶囊/散治疗新生儿黄疸的所有随机对照试验(randomized controlled trial,RCT)和前瞻性非随机对照试验(non-randomized controlled trial,non-RCT),纳入文献时间从2001年1月至2014年12月。按照纳入与排除标准选择文献、提取资料并评价质量后,采用Cochrane协作网提供的RevMan 5.2软件进行Meta分析。结果检索文献无RCT研究,纳入17篇前瞻性non-RCT研究文献,合计1 988例患者,其中治疗组(对照组常规治疗措施+双歧杆菌三联活菌胶囊/散)1 004例,对照组984例。Meta分析结果显示:治疗组的有效率优于对照组[OR=3.36,95%CI(2.14,5.27),P<0.001];治疗组新生儿黄疸持续天数低于对照组[Mean Deviation(MD)=-2.13,95%CI(-2.63,-1.62),P<0.001];治疗后第3天经皮胆红素值治疗组低于对照组[MD=-29.66,95%CI(-42.78,-16.54),P<0.001]。结论双歧杆菌三联活菌胶囊/散与常规治疗措施联用可以提高新生儿黄疸的总体疗效,同时可以有效减少新生儿黄疸的持续天数,加快黄疸的消退。

Objective To evaluate the effect of Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules/Powder in treating neonatal jaundice by Meta-analysis.Methods Databases including CNKI,WanFang Data,VIP,PubMed,Embase and Web of Science were searched from inception to December,2015 to collect all randomized controlled trials（RCTs）and prospective non-randomized controlled trials（non-RCTs）on Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules/Powder in treating neonatal jaundice.The included time of all studies ranges from January 2001 to December 2014 and the studies were selected according to the inclusion and exclusion criteria.The data were extracted,the methodological qualities of the included studies were assessed,and the Meta-analysis was performed with RevMan5.2.Results A total of 17 prospective non-RCTs involving 1,988 patients were included,including 1,004 patients from treatment group（Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules/Powder plus conventional treatment）and 984 patients from control group（conventional treatment）.The total effective rate of the treatment group was superior to that of the control group（OR=3.36,95%CI2.14 to 5.27,P〈0.001）;the duration of neonatal jaundice of the treatment group was shorter than that of the control group（MD=-2.13,95%CI-2.63to-1.62,P〈0.001）;percutaneous bilirubin value on the third day after treatment of the treatment group was lower than that of the control group（MD=-29.66,95%CI-42.78to-16.54,P〈0.001）.Conclusion Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules/Powder combined with conventional drugs can improve the effective rate of treating neonatal jaundice,reduce the duration and accelerate jaundice subsided.